

Relevant litteratur - alternativkostnad

Barnsley P, et al. (2013). Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold. [Office of Health Economics](#).

Charlton V (2025). What price is society willing to pay for new drugs? [The Lancet](#).

Claxton K, et al (2015). Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. [National Institute for Health and Care Research](#).

Claxton K, et al (2015). Methods for the Estimation of the NICE Cost Effectiveness Threshold. [Centre for Health Economics, The University of York](#).

Claxton K., et al (2024). Sampson and Cookson's commentary: What is it good for? [Health Policy](#).

Dolan P, et al (2005). QALY maximisation and people's preferences: a methodological review of the literature. [Health Economics](#).

Edney CL, et al (2018). Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System. [PharmacoEconomics](#).

Edney CL, et al (2021). Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. [PharmacoEconomics](#).

Espinosa O, et al (2024). Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges. [Applied Health Economics and Health Policy](#)

Helse- og omsorgsdepartementet. (2016). Verdier i pasientens helsetjeneste. [Meld. St.34 \(2015-2016\)](#).

Helse- og omsorgsdepartementet. (2025). Helse for alle. Rettferdig prioritering i vår felles helsetjeneste. [Meld. St. 21 \(2024-2025\)](#).

Lomas J, et al (2019). Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. [Value in Health](#).

Magnussengruppen. (2015). På ramme alvor - Alvorlighet og prioritering. [Helse- og omsorgsdepartementet](#).

Martin S, et al (2023). The impact of different types of NHS expenditure on health: Marginal cost per QALY estimates for England for 2016/17. [Health Policy](#).

Martin S, et al (2011). Comparing costs and outcomes across programmes of health care. [Health Economics](#).

Martin S, et al (2008). Does health care spending improve health outcomes? Evidence from English programme budgeting data. [Journal of Health Economics](#).

Marseille E, et al (2014). Thresholds for the cost–effectiveness of interventions: alternative approaches

McCabe C, et al (2008): The NICE cost-effectiveness threshold: what it is and what that means. [PharmaEconomics](#).

Naci H, et al (2025). Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis. [The Lancet](#).

NOU 2014: 12. (2014). Åpent og rettferdig – prioriteringer i helsetjenesten. [Helse- og omsorgsdepartementet](#).

Oslo economics (2024). Marginalkostnader i spesialisthelsetjenesten. [Oslo Economics](#).

Pichon-Riviere A, et al (2023). Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. [The Lancet](#).

Phelps CE (2019). A New Method to Determine the Optimal Willingness to Pay in Cost-Effectiveness Analysis. [Value Health](#).

Polak TB, et al (2021) Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020. [BMJ Open](#).

Raftery JP (2014). NICE's Cost-Effectiveness Range: Should it be Lowered? [PharmacoEconomics](#).

Richardson J. et al (2019). Health technology assessment (HTA) and economic evaluation: efficiency or fairness first. [Journal of Market Access Health Policy](#).

Sampson C, et al (2022). Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy. [Appl Health Econ Health Policy](#).

Schwarzer R, et al (2015). Systematic overview of cost-effectiveness thresholds in ten countries across four continents. [Journal of Comparative Effectiveness Research](#).

Siverskog J, et al (2019). Estimating the marginal cost of a life year in Sweden's public healthcare sector. [The European Journal of Health Economics](#).

Stadhouders N et al (2019). The marginal benefits of healthcare spending in the Netherlands: Estimating cost-effectiveness thresholds using a translog production function. [HealthEconomics](#).

Strohmaier C, et al (2024). Threshold values in health economic evaluations and decision-making. [Institute for Health Technology Assessment GmbH](#).

Thokala P, et al (2018). Cost-Effectiveness Thresholds: the Past, the Present and the Future. [Pharmacoeconomics](#).

Vallejo-Torres L, et al (2021). Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries. [Applied Health Economics and Health Policy](#).

Vallejo-Torres L, et al (2018). Estimating a cost-effectiveness threshold for the Spanish NHS. [HealthEconomics](#)

Woods B, et al (2016). Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. [Value in Health](#).

Walton MJ, et al (2019). A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process. [Pharmacoeconomics](#).